Fig. 2
Fer-1 alleviated renal ferroptosis triggered by hyperhomocysteinemia without altering β-catenin and GPX4 levels. The ferroptosis inhibitor Fer-1 (2 mg/kg/day, i.p.) was administered to mice with hyperhomocysteinemia, and its therapeutic efficacy was evaluated. (A) Western blotting was used to assess the expression of active β-catenin, β-catenin, GPX4, FTH1, and KIM-1 in the kidneys of mice from indicated groups. (B–F) Quantitative analysis of the levels of active β-catenin, β-catenin, GPX4, FTH1, and KIM-1 in Figure (A) was performed. (G–I) Biochemical determination of the levels of Fe2+, MDA, and GSH in the kidney tissues of mice from indicated groups was conducted. (J) Immunohistochemical analysis of β-catenin and GPX4 in the renal tissues was performed. Scale bar, 20 μm. *P < 0.05 vs. the controls; #P < 0.05 vs. hyperhomocysteinemia mice (n = 6). Hcy, homocysteine.
